CN102488814A - 治疗奶牛乳房炎的中药组合物 - Google Patents
治疗奶牛乳房炎的中药组合物 Download PDFInfo
- Publication number
- CN102488814A CN102488814A CN2011104348053A CN201110434805A CN102488814A CN 102488814 A CN102488814 A CN 102488814A CN 2011104348053 A CN2011104348053 A CN 2011104348053A CN 201110434805 A CN201110434805 A CN 201110434805A CN 102488814 A CN102488814 A CN 102488814A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- cow
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 208000031462 Bovine Mastitis Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 164
- 229940079593 drug Drugs 0.000 claims abstract description 65
- 241000218176 Corydalis Species 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000000052 vinegar Substances 0.000 claims abstract description 12
- 235000021419 vinegar Nutrition 0.000 claims abstract description 12
- 208000004396 mastitis Diseases 0.000 claims description 100
- 241000628997 Flos Species 0.000 claims description 32
- 241000245240 Lonicera Species 0.000 claims description 25
- 239000011812 mixed powder Substances 0.000 claims description 20
- 241000545442 Radix Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000009636 Huang Qi Substances 0.000 claims description 18
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 10
- 229940070384 ventolin Drugs 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 52
- 239000008280 blood Substances 0.000 abstract description 36
- 210000004369 blood Anatomy 0.000 abstract description 35
- 230000001737 promoting effect Effects 0.000 abstract description 19
- 208000002193 Pain Diseases 0.000 abstract description 18
- 230000036407 pain Effects 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000004087 circulation Effects 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 244000183685 Citrus aurantium Species 0.000 abstract description 3
- 235000007716 Citrus aurantium Nutrition 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 235000011837 pasties Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 229940099259 vaseline Drugs 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 79
- 239000013521 mastic Substances 0.000 description 21
- 210000000481 breast Anatomy 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 17
- 210000004080 milk Anatomy 0.000 description 17
- 239000008267 milk Substances 0.000 description 17
- 235000009508 confectionery Nutrition 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010007247 Carbuncle Diseases 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 5
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 231100000019 skin ulcer Toxicity 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 229930183118 Tanshinone Natural products 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000006356 dehydrogenation reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- -1 lactone glucoside Chemical class 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 229930189533 tanshinol Natural products 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- CEHVTERMWMYLCP-UHFFFAOYSA-N 1-(hydroxymethyl)-6,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound C1=2OC=C(CO)C=2C(=O)C(=O)C2=C1C=CC1=C2CCCC1(C)C CEHVTERMWMYLCP-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006272 Breast mass Diseases 0.000 description 2
- RFKQJTRWODZPHF-UHFFFAOYSA-N Dehydrocorydaline Natural products COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(C)=C3C2=C1 RFKQJTRWODZPHF-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 229930006722 beta-pinene Natural products 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HKIDROLXYXYQOZ-UHFFFAOYSA-N dehydrocorydaline Chemical compound C1C2=C(OC)C(OC)=CC=C2C(C)=C2N1CCC1=C2C=C(OC)C(OC)=C1 HKIDROLXYXYQOZ-UHFFFAOYSA-N 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- UETZJEZFLKASPR-UZWIWUQPSA-N kobusone Chemical compound O=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 UETZJEZFLKASPR-UZWIWUQPSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 2
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- NUIFDRMJKLJEJE-HNNXBMFYSA-N (4aS)-1,4a-dimethyl-7-propan-2-yl-3,4,5,6-tetrahydronaphthalen-2-one Chemical compound O=C1CC[C@]2(C)CCC(C(C)C)=CC2=C1C NUIFDRMJKLJEJE-HNNXBMFYSA-N 0.000 description 1
- KUFXJZXMWHNCEH-DOMZBBRYSA-N (4as,7r)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1CC(=O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C KUFXJZXMWHNCEH-DOMZBBRYSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- CETREAVXUDHZGK-UHFFFAOYSA-N 1-(hydroxymethyl)-6-methylnaphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound C12=CC=C3C(C)=CC=CC3=C2C(=O)C(=O)C2=C1OC=C2CO CETREAVXUDHZGK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N Azulene Natural products C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- YALFFHSIVPCNLF-QPSCCSFWSA-N Cyperolone Chemical compound C1[C@H](C(=C)C)CC[C@@]2(C)CC[C@H](O)[C@]21C(C)=O YALFFHSIVPCNLF-QPSCCSFWSA-N 0.000 description 1
- YALFFHSIVPCNLF-UHFFFAOYSA-N Cyperolone Natural products C1C(C(=C)C)CCC2(C)CCC(O)C21C(C)=O YALFFHSIVPCNLF-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RGRYQUWGSJPMMK-SBJFKYEJSA-N Epoxyguaiene Natural products C(=C)(C)[C@H]1C[C@@]23[C@@H](C)CC[C@@]2([C@@H](C)CC1)O3 RGRYQUWGSJPMMK-SBJFKYEJSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CZFHAODYOVXPIQ-BARDWOONSA-N Isocyperol Chemical compound C1C[C@@H](O)C(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C CZFHAODYOVXPIQ-BARDWOONSA-N 0.000 description 1
- CZFHAODYOVXPIQ-UHFFFAOYSA-N Isocyperol Natural products C1CC(O)C(=C)C2CC(C(=C)C)CCC21C CZFHAODYOVXPIQ-UHFFFAOYSA-N 0.000 description 1
- BSFUDCIRZBAPDS-TUAOUCFPSA-N Isokobusone Chemical compound C([C@H](O)C(=C)CC1)CC(=O)[C@@H]2[C@@H]1C(C)(C)C2 BSFUDCIRZBAPDS-TUAOUCFPSA-N 0.000 description 1
- BSFUDCIRZBAPDS-UHFFFAOYSA-N Isokobusone Natural products C1CC(=C)C(O)CCC(=O)C2C1C(C)(C)C2 BSFUDCIRZBAPDS-UHFFFAOYSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- SVCXTVVQYVKZTG-SNVBAGLBSA-N Przewaquinone B Natural products Cc1cccc2c3C(=O)C(=O)C4=C(OC[C@H]4CO)c3ccc12 SVCXTVVQYVKZTG-SNVBAGLBSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- NUWMTBMCSQWPDG-SDDRHHMPSA-N Rotundone Chemical compound C1([C@H](CC[C@H](C2)C(C)=C)C)=C2[C@@H](C)CC1=O NUWMTBMCSQWPDG-SDDRHHMPSA-N 0.000 description 1
- NUWMTBMCSQWPDG-UHFFFAOYSA-N Rotundone Natural products C1C(C(C)=C)CCC(C)C2=C1C(C)CC2=O NUWMTBMCSQWPDG-UHFFFAOYSA-N 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- 235000002905 Rumex vesicarius Nutrition 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- NUIFDRMJKLJEJE-UHFFFAOYSA-N beta-cyperone Natural products O=C1CCC2(C)CCC(C(C)C)=CC2=C1C NUIFDRMJKLJEJE-UHFFFAOYSA-N 0.000 description 1
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 description 1
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 1
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- NETQOOYQUZAJCL-UHFFFAOYSA-N kobusone Natural products CC1(C)CC2C1CCC3(C)OC3CC2=O NETQOOYQUZAJCL-UHFFFAOYSA-N 0.000 description 1
- UETZJEZFLKASPR-UHFFFAOYSA-N kobustone Natural products O=C1CCC2OC2(C)CCC2C(C)(C)CC21 UETZJEZFLKASPR-UHFFFAOYSA-N 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗奶牛乳房炎的中药组合物,以重量份表示,该治疗奶牛乳房炎的中药组合物中含有原料药丹参15~30份,当归5~10份,黄芪1~5份,赤芍5~10份,延胡索5~10份,香附5~10份,枝壳2~5份,青皮5~10份,金银花15~20份,蒲公英5~10份和甘草3~5份。该组合物可以制备成膏状体,将各种原料药进行粉碎,得到各种原料药的细粉,将粉碎后的各种原料药细粉搅拌混合均匀,得到混合药粉,然后在混合药粉中加入食醋和医用凡士林,搅拌均匀成膏状体。本发明中成药组方中,诸药合用,具有疏肝化淤、和血止血、行气止痛、抗菌消炎、补气固表,托疮生肌、增强机体免疫力等诸多功能。利用本发明中成药治疗和预防奶牛乳房炎效果显著,并且成本低廉、无任何毒副作用。
Description
技术领域
本发明涉及一种兽药组合物,特别是涉及一种用于治疗奶牛乳房炎的中药组合物。
背景技术
奶业是我国畜牧业发展的支柱产业之一,它对于改善城乡居民膳食结构、提高全民身体素质,促进农村产业结构,调整城乡协调发展,农民增收,带动国民经济相关产业的发展具有重要意义。特别是“十五”以来,国家把奶业作为畜牧产业发展的重点。但是,奶牛乳房炎的发生成为影响奶业经济效益的最大因素。它的发病率很高,国外一般在25~60%,国内的发病率一般在20~70%。由于乳房炎的感染率高,治愈率低,所以给奶牛业造成了巨大损失。全世界每年因乳房炎造成的损失高达350亿美元,仅美国的损失就达20亿美元。在英国奶牛乳房炎造成的直接经济损失可达2.67亿英镑。我国每年也因隐性乳房炎造成的损失约达1.35 亿元人民币。乳房炎的发生不仅造成严重的经济损失,而且危害消费者健康。乳房炎患牛所产的乳汁中含有大量的炎性因子、病原微生物及其产生的毒素以及残留的抗菌类药物,都可危害消费者的身体健康。这对于当今奶类食品已从营养保健品转变为人们日常的食品来说危害更加严重。其安全防治问题已日益为人们所关注。
奶牛乳房炎是奶牛乳房以乳腺叶间组织或腺体发炎而形成的乳房疾病,中兽医属于“乳痈”范畴。乳房炎根据临床表现可分为隐性乳房炎和临床乳房炎。所谓隐性乳房炎是指肉眼看不见乳汁和乳房变化,不显任何乳房临床症状,但乳汁用细菌学检查和生物化学检查易发生明显变化,这类乳房炎发病率远高于临床型,危害最大;临床型乳房炎是乳房和乳汁均用肉眼可以见到明显的改变。
奶牛乳房炎的发病原因主要有:1、微生物因素:引起奶牛乳房炎的病原微生物主要是多种非特定的微生物,各种微生物的感染程度因地区不同而异,其中有多种细菌、病毒、支原体。病原微生物浸入乳头管引起乳房炎是人们公认的主要途径。2、环境因素:奶牛乳房炎传播的主要途径是通过接触感染。如牛舍尘埃多、不清洁、不消毒;牛粪堆积门外或堆积在排尿沟内;牛床潮湿,挤奶时随意将头几把奶挤在牛床上,又不及时冲洗、消毒;牛棚污染严重;真空泵调节器不清洁,或挤奶器上的橡皮管不经常更换,或清洗挤奶器不加任何消毒剂等。3、挤奶技术:若挤奶员挤奶技术不熟练或技术不当,会使乳头黏膜上皮损伤;机器挤奶时间过长,负压过高或抽动过速,也会损伤乳头皮肤和黏膜;挤奶前手不干净、未挤净乳汁等都给细菌侵入乳房创造了条件。4、饲养管理:对于高产奶牛,高能量、高蛋白质的日粮有利于保护和提高产奶量,同时也增加了乳房的负荷,使机体的抵抗力降低。
目前,奶牛乳房炎的治疗主要集中在抗生素药物的使用,由此产生的药物残留问题使人们也逐渐认识到单靠抗菌药物不能从根本上解决奶牛乳房炎的严重问题。
而中兽医认为,乳房炎即乳痈,是由于肝气不疏,经络阻滞,气滞血淤,淤久成痈,甚至热盛肉腐而形成。再加上饲养管理不善,奶牛久卧湿热之地,湿热毒气上蒸,侵害乳房,致乳房气血凝滞,瘀结而生痈肿。
目前,关于治疗奶牛乳房炎方面的中药也有不少专利文献报道。例如:1、申请号为200610150996.X、发明名称为“一种防治奶牛乳房炎的中药组合物”的发明专利,该专利公开的中药组合物是由蒲公英4-6份、金银花3-6份、紫花地丁2-6份、当归4-6份、瓜蒌3-7份、牛蒡子3-6份、川芎2-5份、青皮3-7份、黄芩4-6份、连翘2-6份配制而成。2、申请号为200810152777.4、发明名称为“治疗奶牛乳房炎的中药组合物”,该专利的中药组合物是由蒲公英140-160份,王不留行70-90份,通草70-90份,金银花95-105份,黄连95-105份,地丁95-105份,赤芍40-60份,连翘40-60份,生甘草40-60份,凤尾草70-90份,皱叶酸模40-60份配制而成。
发明内容
本发明要解决的技术问题是提供一种治疗奶牛乳房炎的中药组合物。本发明中成药组方中,诸药合用,具有疏肝化淤、和血止血、行气止痛、抗菌消炎、补气固表,托疮生肌、增强机体免疫力等诸多功能。利用本发明中成药治疗和预防奶牛乳房炎效果显著,并且成本低廉、无任何毒副作用。
为了解决上述问题,本发明采用的技术方案是:
本发明提供一种治疗奶牛乳房炎的中药组合物,以重量份表示,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参15~30份,当归5~10份,黄芪1~5份,赤芍5~10份,延胡索5~10份,香附5~10份,枝壳2~5份,青皮5~10份,金银花 15~20份,蒲公英5~10份和甘草3~5份。
根据上述的治疗奶牛乳房炎的中药组合物,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参20~25份,当归7~9份,黄芪2~3份,赤芍7~9份,延胡索7~9份,香附7~9份,枝壳2~5份,青皮7~9份,金银花 16~18份,蒲公英7~9份和甘草3~5份。
根据上述的治疗奶牛乳房炎的中药组合物,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参15~20份,当归5~7份,黄芪1~3份,赤芍5~7份,延胡索5~7份,香附8~10份,枝壳2~5份,青皮8~10份,金银花 15~18份,蒲公英5~7份和甘草3~5份。
根据上述的治疗奶牛乳房炎的中药组合物,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参25~30份,当归8~10份,黄芪3~5份,赤芍8~10份,延胡索8~10份,香附5~7份,枝壳2~5份,青皮5~8份,金银花 18~20份,蒲公英8~10份和甘草3~5份。
根据上述的治疗奶牛乳房炎的中药组合物,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参30份,当归10份,黄芪5份,赤芍10份,延胡索10份,香附10份,枝壳5份,青皮10份,金银花20份,蒲公英10份和甘草5份。
根据上述的治疗奶牛乳房炎的中药组合物,所述中药组合物的剂型为膏状。
根据上述的治疗奶牛乳房炎的中药组合物,所述中药组合物的剂型为膏状,膏状中药组合物的制备方法为:按照上述治疗奶牛乳房炎中药组合物的原料药配比比例称取各种原料药,将各种原料药进行粉碎,得到各种原料药的细粉,各种原料药细粉的细度为120~150目,将粉碎后的各种原料药细粉搅拌混合均匀,得到混合药粉,然后在混合药粉中加入食醋和医用凡士林,搅拌均匀成膏状体。
根据上述的治疗奶牛乳房炎的中药组合物,所述食醋的加入量占混合药粉总重量的45~55%;所述医用凡士林的加入量占混合药粉总重量的45~60%。
本发明组方中各原料药的特性如下:
丹参:本品主含脂溶性成分和水溶性成分。脂溶性成分包括丹参酮Ⅰ、丹参酮ⅡA、丹参酮ⅡB、丹参酮Ⅲ、隐丹参酮、羟基丹参酮、丹参酸甲酯、紫丹参甲素、紫丹参乙素、丹参新酮、丹参醇Ⅰ、丹参醇Ⅱ、丹参醇Ⅲ、丹参酚、丹参醛等。水溶性成分主要含有丹参素,丹参酸甲、乙、丙,原儿茶酸、原儿茶醛等。本品能扩张冠脉,增加冠脉血流量,改善心肌缺血,促进心肌缺血或损伤的恢复,缩小心肌梗死范围;能提高耐缺氧能力,对缺氧心肌有保护作用;能改善微循环,促进血液流速;能扩张血管,降低血压。能改善血液流变性,降低血液粘度,抑制血小板和凝血功能,急活纤溶,对抗血栓形成;能保护红细胞膜。能调节血脂,抑制动脉粥样硬化斑块的形成。能保护肝细胞损伤,促进肝细胞再生,有抗肝纤维化作用。能促进骨折和皮肤切口的愈合。能保护胃粘膜、抗胃溃疡。对中枢神经有镇静和镇痛作用。具有改善肾功能、保护缺血性肾损伤的作用。具有抗炎、抗过敏的租用。对金黄色葡萄球菌、多种杆菌以及钩端螺旋体等有不同程度的抑制作用。
丹参性微寒、味苦,归心、肝二经;具有活血调经,祛瘀止痛,凉血消痈,清心除烦,养血安神等功效。主治癥瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛等症。
当归:性温,味辛、甘;入心、肝、脾、肺四经。功效主治:1、养血活血:本品味甘而重,故专能补血,其气轻而辛,又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药也。本品为良好的补血药,故适用于血虚引起的各种证候。2、活血止痛:当归能逐淤血,生新血,使血脉通畅与气并行,周流不息。常用于跌打损伤瘀痛,痈肿血滞疼痛,产后瘀滞腹痛,风湿痹痛及经络不利等证,本品具有良好的活血止痛作用。3、润肠通便:用于血虚津少,肠燥便秘。症见:大便秘结,面色无华,心悸怔忡,头晕目眩。4、降逆止咳:当归辛温,入肺经,有宣肺平喘,降逆止咳之功。5、当归宜用于血虚头痛及瘀血头痛者。
黄芪:性微温,味甘;入肺、脾二经。功效主治:1、补气升阳:黄芪甘温,甘能补,有滋补强壮作用。为补气之要药。具有补气健脾、益气升阳、补中助阳、补气生血之功效。2、补气摄血:常用黄芪治因脾气虚不能统血而致的各种出血,尤在大出血时,有形之血不能速生,无形之气所当急固。此时重用黄芪,可收止血生血之奇效。3、补气行滞、祛瘀散结:气滞则血不行而瘀阻,症见肢体麻木,关节痹痛,半身不遂,胸闷胁张,面色晦暗,舌紫或有瘀点,瘀斑,脉沉涩,用黄芪补气养血,可收祛瘀散结之效。4、益气固表:黄芪甘温,主补肺脾之气,肺气旺,则表固汗止。5、补气益阴:用黄芪补益气阴,收健脾胃,布津液,秘固精气而止汗缩泉之捷效。6、利水消肿。7、温里散寒:黄芪味甘而温,用治血痹,甚和经义。8、托脓生肌:黄芪主痈疽,久败疮,排脓止痛,大风癫疾,五痔漏,为疮家之要药。9、强体质、延年益寿。
黄芪提取物中含有的黄芪甲甙具有补气固表、利尿排毒、排脓、敛疮、生肌之功效。适用于进食量降低及粪便稀薄等症状,黄芪提取物具有增强免疫力,增强能量,降低心肌耗氧量、减慢心率,舒张冠状动脉,加强心肌收缩力等作用,同时还有增强免疫力的作用,可以诱导机体产生干扰素,还具有清热解毒的功效,可以有效缓解症状。
赤芍:本品含芍药苷、芍药内酯苷、氧化芍药苷、苯甲酰芍药苷、芍药吉酮、芍药新苷、没食子鞣质、苯甲酸、挥发油、脂肪油、树脂等。本品能扩张冠状动脉、增加冠脉血流量;赤芍水提液、赤芍苷、赤芍成分及其衍生物有抑制血小板聚集作用;其水煎剂能延长体外血栓形成时间,减轻血栓干重;所含芍药苷有镇静、抗炎止痛作用;芍药流浸膏、芍药苷有抗惊厥作用;赤芍、芍药苷有解痉作用;赤芍对肝细胞DNA的合成有明显的增强作用,对多种病源微生物有较强的抑制作用。
赤芍性微寒、味苦,归肝经;具有清热凉血,散瘀止痛之功效。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。
延胡索:本品主含生物碱,现已提出十余种。延胡索甲素、乙素、丙素、丁素、戊素、己素、庚素、辛素、壬素、葵素、子素、丑素、寅素,β-高白屈菜碱、黄连碱、去氢延胡索甲素C、去氢延胡索甲素碱、延胡索胺碱、去氢延胡索胺碱及古伦胺碱等。现代药理研究表明延胡索的多种制剂均有明显镇痛作用;延胡索全碱对心肌收缩力有抑制作用,能显著增加冠脉流量,乙素、丑素和脱氢延胡索碱均能使心率减慢,血压下降,冠脉流量增加,同时心肌耗氧量增加,延胡索醇提取物有显著扩张冠状血管、降低冠脉阻力与增加血流量的作用,延胡索可明显提高对缺氧的耐受能力,脱氢延胡索碱有扩张冠状血管、提高冠脉血流量、改善心肌耐缺氧能力作用,对心肌缺血、坏死亦有保护作用。延胡索的一些成分对胃溃疡有保护作用。
延胡索性温,味辛、苦,归心、肝、脾三经;具有活血行气、活血散瘀等功效。
香附:为莎草科植物,莎草的干燥根径,秋季采挖,燎去毛须,置沸水中略煮或蒸透后晒干生用,也可醋炙用。本品性辛、平,味微苦、甘,归肝、脾、三焦经。功效主治:本品具有疏肝解郁、调经止痛、理气调中之功效。
香附:含葡萄糖、果糖、淀粉、挥发油。挥发油中主要为香附子烯、香附醇、异香附醇、并含β-蒎烯、莰烯、1, 8-桉叶素、柠檬烯、芹子三烯、β-芹子烯、α-香附酮、β-香附酮、香附醇酮、莎草薁酮、环氧莎草薁酮、考布松及异考布松。亦含三萜类、黄酮类及生物碱等。香附能抑制子宫的收缩,对子宫肌张力的弛缓作用;具有明显的镇痛作用和抗菌、抗炎作用。
枳壳:各种枳壳均含挥发油和黄酮甙等物质。玳玳花未成熟果实的果皮中含新橙皮甙;果实成熟时,新橙皮甙消失而柚皮甙增多,接近成熟的酸橙果实中含维生素 C,从香圆和枸橘中分离得同一种生物碱样物质。本品具有升压作用,具有抗过敏等作用。
枳壳性凉,味苦、辛,入肺、脾、大肠经。具有破气消积、下气祛痰、行气止疼、利气消肿等功效。主治食滞痞满、下痢后重、癥瘕积聚、皮肤风痒、肠风下血等证。
青皮:性温,味苦、辛、微酸;入肝、胆、胃、脾四经,具有疏肝破气、消积散结、化痰消瘿等功效。主治胁肋胀痛、乳房疼痛、疝气疼痛、癥瘕积聚、食积气滞等证。
青皮中含挥发油,挥发油中主要成分为D-柠檬烯, 还含β-月桂烯,α-及β-蒎烯等, 另含黄酮类成分橙皮甙、新橙皮甙,、柑橘素、二氢川陈皮素及5-去甲二氢川陈皮素;另含辛弗林(对羟福林)。具有祛痰平喘作用,舒张肠道平滑肌作用,升压作用。
金银花:性寒、味甘,入肺、胃、心、脾四经。功效主治:1、辛凉解表:本品甘寒,其花性轻扬上浮,清香散发,故有发汗解表之功。多用于外感风热,温病初起等证。2、清热解毒:本品甘寒,入肺胃二经,清热解毒功力甚强,在外科中常用之,一般用于有红肿热痛的疮痈肿毒,对辨证上属于“阳证”的病症,最为合适。3、凉血止痢:本品疏散风热,必走肺经,肺与大肠相表里,故归大肠经,所以有解毒凉血止痢之效。
现代药理研究表明其具有抗菌、抗病毒、抑制溃疡及增强免疫功能的作用,试验表明金银花对伤寒杆菌、副伤寒杆菌、大肠杆菌、变形杆菌、绿脓杆菌、百日咳杆菌、霍乱弧菌、葡萄球菌、链球菌、肺炎双球菌、脑膜炎球菌等均有抑制作用。具有光谱抗菌药效,加强机体免疫力,对奶牛乳房炎有特效。金银花中所含有的绿原菌具有抗菌、抗病毒、止血、抗肝炎等作用,同时还具有增强免疫力的作用,可以诱导机体产生干扰素,提高奶牛的机体机能,缓解病情;此外金银花中所含有的绿原菌还具有清热解毒的功效,可以有效缓解症状。
甘草:性平,味甘;入心、肺、脾、胃四经。功效主治:甘草具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药之功效。常用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
蒲公英:本品含蒲公英甾醇、胆碱、菊糖、果胶;蒲公英醇、豆甾醇、β-香树脂醇、β-谷甾醇、蒲公英赛醇、蒲公英素、蒲公英苦素和维生素A、B、C等。本品具有的药理作用:1、对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、变形杆菌、痢疾杆菌、伤寒杆菌等及卡他球菌亦有一定的杀菌作用;2、对某些真菌亦有抑制作用;2、保肝、利胆作用;3、抗胃溃疡作用;4、本品有抗人体肺癌作用。有促进妇女乳汁分泌作用。
本品性寒,味甘、苦,入肝、胃二经;具有清热解毒、清热利湿、通利小便等功效。
甘草中含三萜类、黄酮类、生物碱、多糖等成分。甘草有抗心率失常作用;有抗溃疡,抑制胃酸分泌,缓解胃肠平滑肌痉挛及镇痛作用,并与芍药的有效成分芍药苷有协同作用;能促进胰液分泌;有明显的镇咳作用,祛痰作用也较为显著,还有一定平喘作用;有抗菌、抗病毒、抗炎、抗过敏作用;能保护发炎的咽喉和气管粘膜;对某些毒物有类似葡萄糖醛酸的解毒作用;有类似似肾上腺皮质激素样作用;还有利尿、降脂、保肝等作用。
本发明组方中诸药相配,使内湿得清,内热得解,提高奶牛机体机能,缓解病情;患病奶牛服用后可使得诸症状减轻并得以痊愈。
本发明的积极有益效果:
1、本发明是在中兽医学卫气营血辨证理论方法的指导下,筛选出多种中草药按君臣佐使原则组方,诸药合用,从根本上治疗和防止乳房炎。防治率可达95%以上,治愈率达80%以上。
2、本发明中药组合物中含有蒲公英、金银花具有清热解毒,消痈散结的作用。对金黄色葡萄球菌、绿脓杆菌以及皮肤真菌具有很强的抑制作用;组合物中还含有黄芪、丹参、当归、赤芍,具有补气固表、托疮生肌、行气、养血,改善微循环,促进血液流通,促进伤口愈合等作用。
3、本发明中药组合物采用纯中药,结合奶牛乳房炎的发病机理和产生的临床症状进行组方。诸药合用,具有疏肝化瘀、和血止血、行气止痛、抗菌消炎、补气固表、托疮生机、增强机体免疫力等诸多功能。
4、本发明中药组合物成本低廉、使用方便,治疗效果明显,无任何毒副作用。适用于奶牛临床型乳腺炎和隐形乳房炎的治疗与防治,其防治率可达95%以上,治愈率达80%以上。
5、本发明中药组合物为纯中药组成,组方合理。中药的配伍原则是“增效减毒”。因此,配伍不同的药物所体现的药理作用也不同。本发明药物配伍,全方得以标本兼治、扶正祛邪、全面调整、平衡阴阳。混合上述原料制成的药膏,对奶牛乳房炎的治疗具有显著作用,有独特的疗效。本发明根据“综合调节、群防群治”的治疗原则,本着“健脾祛湿、滋阴补气,清热解毒”的原则,在临床试验中的防治率达到95%以上,治愈率达80%以上,疗效显著。
四、具体实施方式:
以下结合实施例对本发明作进一步阐述,但实施例部分并不限制本发明所保护的范围。
实施例1:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参30份,当归10份,黄芪5份,赤芍10份,延胡索10份,香附10份,枝壳5份,青皮10份,金银花20份,蒲公英10份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物的剂型为膏体,其制备方法为按照上述治疗奶牛乳房炎中药组合物的原料药配比比例称取各种原料药,将各种原料药进行粉碎,得到各种原料药的细粉,各种原料药细粉的细度为120目,将粉碎后的各种原料药细粉搅拌混合均匀,得到混合药粉,然后在混合药粉中加入食醋和医用凡士林,食醋的加入量占混合药粉总重量的45%,所述医用凡士林的加入量占混合药粉总重量的50%,搅拌均匀成膏状体。
实施例2:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参20份,当归8份,黄芪3份,赤芍6份,延胡索7份,香附8份,枝壳3份,青皮6份,金银花15份,蒲公英6份和甘草3份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1不同之处在于:各种原料药细粉的细度为150目,食醋的加入量占混合药粉总重量的50%,所述医用凡士林的加入量占混合药粉总重量的55%。
实施例3:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参15份,当归7份,黄芪2份,赤芍8份,延胡索9份,香附5份,枝壳2份,青皮8份,金银花18份,蒲公英9份和甘草4份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1不同之处在于:各种原料药细粉的细度为130目,食醋的加入量占混合药粉总重量的55%,所述医用凡士林的加入量占混合药粉总重量的60%。
实施例4:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参18份,当归5份,黄芪1份,赤芍5份,延胡索5份,香附9份,枝壳4份,青皮5份,金银花19份,蒲公英5份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1不同之处在于:各种原料药细粉的细度为140目,食醋的加入量占混合药粉总重量的45%,所述医用凡士林的加入量占混合药粉总重量的45%。
实施例5:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参28份,当归9份,黄芪4份,赤芍7份,延胡索8份,香附7份,枝壳3份,青皮7份,金银花16份,蒲公英7份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1不同之处在于:各种原料药细粉的细度为150目,食醋的加入量占混合药粉总重量的50%,所述医用凡士林的加入量占混合药粉总重量的50%。
实施例6:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参28份,当归7份,黄芪3份,赤芍8份,延胡索6份,香附9份,枝壳4份,青皮8份,金银花20份,蒲公英10份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1相同。
实施例7:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参20份,当归7份,黄芪2份,赤芍7份,延胡索7份,香附7份,枝壳2份,青皮7份,金银花16份,蒲公英7份和甘草3份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例5相同。
实施例8:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参23份,当归8份,黄芪3份,赤芍8份,延胡索8份,香附8份,枝壳4份,青皮8份,金银花17份,蒲公英8份和甘草4份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例5相同。
实施例9:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参25份,当归9份,黄芪3份,赤芍9份,延胡索9份,香附9份,枝壳5份,青皮9份,金银花18份,蒲公英9份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例5相同。
实施例10:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参25份,当归8份,黄芪3份,赤芍8份,延胡索8份,香附5份,枝壳2份,青皮5份,金银花18份,蒲公英8份和甘草3份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例4相同。
实施例11:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参27份,当归9份,黄芪4份,赤芍9份,延胡索9份,香附6份,枝壳3份,青皮7份,金银花19份,蒲公英9份和甘草4份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例4相同。
实施例12:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参30份,当归10份,黄芪5份,赤芍10份,延胡索10份,香附7份,枝壳5份,青皮8份,金银花20份,蒲公英10份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例4相同。
实施例13:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参15份,当归5份,黄芪1份,赤芍5份,延胡索5份,香附8份,枝壳2份,青皮8份,金银花15份,蒲公英5份和甘草3份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例4相同。
实施例14:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参18份,当归6份,黄芪2份,赤芍6份,延胡索6份,香附9份,枝壳3份,青皮9份,金银花17份,蒲公英6份和甘4份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1相同。
实施例15:与实施例1基本相同,不同之处在于:
本发明治疗奶牛乳房炎的中药组合物的原料药组成为:以重量份表示,丹参20份,当归7份,黄芪3份,赤芍7份,延胡索7份,香附10份,枝壳5份,青皮10份,金银花18份,蒲公英7份和甘草5份。
本发明治疗奶牛乳房炎的中药组合物膏体的制备方法与实施例1相同。
临床试验:
本发明中药组合物膏状体的使用方法:将患病奶牛乳区清洗干净,涂抹于乳房表层。
应用实例一:
随机选取70头临床型乳腺炎奶牛,139个乳区,临床症状表现为:乳房发红、水肿,感染乳区变硬,触诊乳房时可发现有大小不等的硬块,凝乳汁中有凝乳块或脓性分泌物。
将随机选取的70头患病奶牛,139乳区清洗干净,将本发明药物膏体涂抹于表层,用药5天后,治愈率达92.5%。
本发明药物膏体的原料药配比组成详见实施例1。
应用实例二:
随机选取100头经CMT (美国加州乳房炎检验法)为隐性乳房炎奶牛的260个乳区,将患病奶牛乳区清洗干净,将本发明药物膏体涂抹于表层,用药5天后,乳汁CMT检测症状减轻,治愈率达79%,连续用药8天后,治愈率达89%。
本发明药物膏体的原料药配比组成详见实施例6。
应用实例三:
随机选取50头干奶期临床型乳腺炎奶牛,85个乳区,临床症状表现为:乳房发红、水肿,感染乳区变硬,触诊乳房时可发现有大小不等的硬块,凝乳汁中有凝乳块或脓性分泌物。
将随机选取的50头干奶期临床型乳腺炎奶牛,85个乳区清洗干净,将本发明药物膏体涂抹于表层,用药5天后,治愈率达91.5%。
本发明药物膏体的原料药配比组成详见实施例12。
Claims (8)
1.一种治疗奶牛乳房炎的中药组合物,其特征在于:以重量份表示,所述治疗奶牛乳房炎的中药组合物中含有原料药丹参15~30份,当归5~10份,黄芪1~5份,赤芍5~10份,延胡索5~10份,香附5~10份,枝壳2~5份,青皮5~10份,金银花 15~20份,蒲公英5~10份和甘草3~5份。
2.根据权利要求1所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述治疗奶牛乳房炎的中药组合物中含有原料药丹参20~25份,当归7~9份,黄芪2~3份,赤芍7~9份,延胡索7~9份,香附7~9份,枝壳2~5份,青皮7~9份,金银花 16~18份,蒲公英7~9份和甘草3~5份。
3.根据权利要求1所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述治疗奶牛乳房炎的中药组合物中含有原料药丹参15~20份,当归5~7份,黄芪1~3份,赤芍5~7份,延胡索5~7份,香附8~10份,枝壳2~5份,青皮8~10份,金银花 15~18份,蒲公英5~7份和甘草3~5份。
4.根据权利要求1所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述治疗奶牛乳房炎的中药组合物中含有原料药丹参25~30份,当归8~10份,黄芪3~5份,赤芍8~10份,延胡索8~10份,香附5~7份,枝壳2~5份,青皮5~8份,金银花 18~20份,蒲公英8~10份和甘草3~5份。
5.根据权利要求1所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述治疗奶牛乳房炎的中药组合物中含有原料药丹参30份,当归10份,黄芪5份,赤芍10份,延胡索10份,香附10份,枝壳5份,青皮10份,金银花20份,蒲公英10份和甘草5份。
6.根据权利要求1所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述中药组合物的剂型为膏状。
7.根据权利要求6所述的治疗奶牛乳房炎的中药组合物,其特征在于,所述中药组合物的剂型为膏状,膏状中药组合物的制备方法为:按照权利要求1~5任一项所述治疗奶牛乳房炎中药组合物的原料药配比比例称取各种原料药,将各种原料药进行粉碎,得到各种原料药的细粉,各种原料药细粉的细度为120~150目,将粉碎后的各种原料药细粉搅拌混合均匀,得到混合药粉,然后在混合药粉中加入食醋和医用凡士林,搅拌均匀成膏状体。
8.根据权利要求7所述的治疗奶牛乳房炎的中药组合物,其特征在于:所述食醋的加入量占混合药粉总重量的45~55%;所述医用凡士林的加入量占混合药粉总重量的45~60%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104348053A CN102488814B (zh) | 2011-12-22 | 2011-12-22 | 治疗奶牛乳房炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104348053A CN102488814B (zh) | 2011-12-22 | 2011-12-22 | 治疗奶牛乳房炎的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102488814A true CN102488814A (zh) | 2012-06-13 |
CN102488814B CN102488814B (zh) | 2013-12-04 |
Family
ID=46180713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011104348053A Expired - Fee Related CN102488814B (zh) | 2011-12-22 | 2011-12-22 | 治疗奶牛乳房炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102488814B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007022A (zh) * | 2012-11-22 | 2013-04-03 | 青岛绿曼生物工程有限公司 | 治疗奶牛乳房炎的复方蜂胶组合物及其制备方法 |
CN103656048A (zh) * | 2013-12-25 | 2014-03-26 | 山东新希望六和集团有限公司 | 用于治疗奶牛乳房炎的药物及其制备方法 |
CN105106524A (zh) * | 2015-07-01 | 2015-12-02 | 太仓市爱农奶牛专业合作社 | 一种治疗奶牛乳房炎的中药及其制备方法 |
CN107951972A (zh) * | 2017-11-27 | 2018-04-24 | 青岛农业大学 | 一种治疗奶牛乳房炎的中药组合外擦药物及其制备方法 |
CN114848680A (zh) * | 2021-02-03 | 2022-08-05 | 四川好医生攀西药业有限责任公司 | 一种用于治疗奶牛乳房炎的组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101612211A (zh) * | 2008-06-24 | 2009-12-30 | 徐后生 | 中药治疗牛乳房炎症的方法 |
CN101897882A (zh) * | 2010-07-06 | 2010-12-01 | 孙士光 | 一种治疗乳腺小叶增生及囊肿的药物 |
-
2011
- 2011-12-22 CN CN2011104348053A patent/CN102488814B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101612211A (zh) * | 2008-06-24 | 2009-12-30 | 徐后生 | 中药治疗牛乳房炎症的方法 |
CN101897882A (zh) * | 2010-07-06 | 2010-12-01 | 孙士光 | 一种治疗乳腺小叶增生及囊肿的药物 |
Non-Patent Citations (2)
Title |
---|
孙茂红等: "奶牛乳房炎的研究进展", 《河北畜牧兽医》 * |
杨英等: "奶牛乳房炎的中医诊治", 《内蒙古畜牧科学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007022A (zh) * | 2012-11-22 | 2013-04-03 | 青岛绿曼生物工程有限公司 | 治疗奶牛乳房炎的复方蜂胶组合物及其制备方法 |
CN103007022B (zh) * | 2012-11-22 | 2014-12-31 | 青岛绿曼生物工程有限公司 | 治疗奶牛乳房炎的复方蜂胶组合物及其制备方法 |
CN103656048A (zh) * | 2013-12-25 | 2014-03-26 | 山东新希望六和集团有限公司 | 用于治疗奶牛乳房炎的药物及其制备方法 |
CN105106524A (zh) * | 2015-07-01 | 2015-12-02 | 太仓市爱农奶牛专业合作社 | 一种治疗奶牛乳房炎的中药及其制备方法 |
CN107951972A (zh) * | 2017-11-27 | 2018-04-24 | 青岛农业大学 | 一种治疗奶牛乳房炎的中药组合外擦药物及其制备方法 |
CN114848680A (zh) * | 2021-02-03 | 2022-08-05 | 四川好医生攀西药业有限责任公司 | 一种用于治疗奶牛乳房炎的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102488814B (zh) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145111B (zh) | 一种治疗霉菌性阴道炎的中药组合物及其制备方法 | |
CN106804643A (zh) | 一种检验科用中药杀菌消毒液 | |
CN103800772A (zh) | 一种防治阴道炎症的妇科外用洗液及其制备方法 | |
CN102488814B (zh) | 治疗奶牛乳房炎的中药组合物 | |
CN102178814B (zh) | 一种治疗滴虫性阴道炎的中药组合物及其制备方法 | |
CN101569739B (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
CN105213941A (zh) | 一种用于治疗小儿腹泻的中药组合物及其制备方法 | |
CN105381352A (zh) | 一种治疗妇科炎症的外用中药洗液 | |
CN104436131A (zh) | 一种用于治疗猪痢疾的药物组合物及其制备方法 | |
CN102512616B (zh) | 一种中草药祛痘组合物 | |
CN102949662B (zh) | 一种用于治疗女性生殖系统炎症的外用中药制剂及其制备方法 | |
CN103239676A (zh) | 一种用于防治细菌性阴道病的外用药物组合物 | |
CN101391065B (zh) | 一种用于治疗急慢性盆腔炎的木鳖子花椒汤 | |
CN103656048B (zh) | 用于治疗奶牛乳房炎的药物及其制备方法 | |
CN102764394A (zh) | 治疗生殖性疾病的化毒和菌中药组合物及其制备方法 | |
CN103099885A (zh) | 具有祛痤疮功能软胶囊及其制备方法 | |
CN104940752A (zh) | 一种治疗外阴溃疡的中药制剂及其制备方法 | |
CN104922449A (zh) | 一种中药消毒液及其制备方法 | |
CN104127774A (zh) | 一种用于治疗皮肤癣的药剂及其制备方法 | |
CN104127765B (zh) | 一种治疗皮肤癣的滴剂及其制备方法 | |
CN103263614A (zh) | 一种预防或治疗阴道炎的药物组合物 | |
CN106177286A (zh) | 一种用于治疗剥脱性角质松解症的中药膏剂 | |
CN105079337A (zh) | 一种预防褥疮的护理液及其制备方法 | |
CN106362084B (zh) | 一种预防妇科疾病的侗医药 | |
CN105396007A (zh) | 一种防治霉菌性阴道炎的妇科外用洗液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 |